OncLive | Obinutuzumab Gains Role in CLL Guidelines OncLive The first-in-class glycoengineered type-2 antibody has demonstrated superior outcomes in combination with chlorambucil to both a rituximab (Rituxan) plus chlorambucil regimen and to chlorambucil alone.1,2. The obinutuzumab combination has been ... |
